Viking Therapeutics (VKTX)

Viking Therapeutics (VKTX) Income Statement


Viking Therapeutics Income Statement

Last quarter (Q1 2024), Viking Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q1, Viking Therapeutics's net income was $-27.36M. See Viking Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
----$ 0.00$ 0.00
Cost of Revenue
Gross Profit
Operating Expense
$ 114.36M$ 100.83M$ 70.36M$ 55.68M$ 42.66M$ 32.69M
Operating Income
$ -114.36M$ -100.83M$ -70.36M$ -55.68M$ -42.66M$ -32.69M
Net Non Operating Interest Income Expense
$ 20.73M$ -14.93M$ 1.59M$ 703.00K$ 3.13M$ 6.90M
Other Income Expense
$ 88.00K$ 88.00K$ 101.00K$ 18.00K$ 40.00K$ 4.00K
Pretax Income
$ -93.72M$ -85.89M$ -69.13M$ -54.99M$ -39.49M$ -25.78M
Tax Provision
$ -29.09M$ -29.09M$ -22.09M$ -2.00K--
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -93.72M$ -85.89M$ -69.13M$ -54.99M$ -39.49M$ -25.78M
Basic EPS
$ -0.93$ -0.91$ -0.90$ -0.71$ -0.54$ -0.36
Diluted EPS
$ -0.93$ -0.91$ -0.90$ -0.71$ -0.54$ -0.36
Basic Average Shares
$ 402.49M$ 94.35M$ 76.83M$ 77.20M$ 72.60M$ 71.96M
Diluted Average Shares
$ 402.49M$ 94.35M$ 76.83M$ 77.20M$ 72.60M$ 71.96M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 114.36M$ 100.83M$ 70.36M$ 55.68M$ 42.66M$ 32.69M
Net Income From Continuing And Discontinued Operation
$ -93.72M$ -85.89M$ -68.87M$ -54.99M$ -39.49M$ -25.78M
Normalized Income
$ -113.77M$ -114.98M$ -91.22M-$ -39.53M$ -25.78M
Interest Expense
-----$ 0.00
$ -71.35M$ -100.83M$ -69.13M$ -54.99M$ -42.66M$ -32.69M
$ -19.55M$ -100.53M$ -67.56M$ -50.77M$ -42.38M$ -32.43M
Currency in USD

Viking Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis